Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faster AMR Drug Reviews And A New Pathogen List On Health Canada’s Agenda

Executive Summary

Health Canada is seeking comments on a proposed list of pathogens that is designed to help the government department understand how it can stimulate the submission of new drugs for beating antimicrobial resistance and facilitate their regulatory approval.

You may also be interested in...



Industry Welcomes EU’s Latest AMR Action Plan, But Public Health Advocates Remain Skeptical

The European Commission has unveiled its second action plan to tackle antimicrobial resistance, this time under the “one health” banner. This new initiative includes a set of guidelines for use by the EU member states when planning their anti-resistance strategies.

EU, US & Japan Tackle Difficulties With Randomized Trials Involving Multi-Drug Resistant Bacteria

The European Medicines Agency has given the Pink Sheet more detail on its recent agreement with its counterparts in the US and Japan to align certain clinical data requirement to stimulate the development of new treatments to fight antimicrobial resistance.

Why Still Nothing For AMR? EMA Asks PRIME Scheme Applicants

The European Medicines Agency wants AMR drug developers to apply for entry on its priority medicine (PRIME) scheme.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel